Corpus Intelligence IC Memo — MOUNTAINVIEW MEDICAL CENTER 2026-04-26 09:37 UTC
IC Memo — MOUNTAINVIEW MEDICAL CENTER
Investment Committee Memorandum | MT | 25 beds | Grade D | EBITDA uplift $534K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

MOUNTAINVIEW MEDICAL CENTER

CCN 271306 | MEAGHER, MT | 25 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

MOUNTAINVIEW MEDICAL CENTER is a 25-bed suburban community hospital in MEAGHER, MT with $7.1M in net patient revenue and a -6.6% operating margin. The hospital serves a payer mix of 19.5% Medicare, 0.3% Medicaid, and 80.1% commercial.

Thesis: Turnaround. Our ML models identify $534K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -6.6% to 0.9% (+749bps).

Net Revenue HCRIS$7.1M
Current EBITDA COMPUTED$-471K
Operating Margin COMPUTED-6.6%
Occupancy HCRIS44.2%
Revenue / Bed COMPUTED$285K
Net-to-Gross HCRIS100.0%
Distress Probability ML57.0%

2. Market Context & Competitive Position

66
MT Hospitals
-9.6%
State Median Margin
48
Comparable Hospitals

MT has 66 Medicare-certified hospitals with a median operating margin of -9.6%. The target's margin of -6.6% places it above the state median. Among 48 size-comparable peers (12-50 beds), the median margin is -9.3%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (12-50), prioritizing same-state peers. 48 hospitals in the comp set.

HospitalStateBedsRevenueMargin
MOUNTAINVIEW MEDICAL CENTER (Target)MT25$7.1M-6.6%
GREAT FALLS CLINIC MEDICAL CENMT20$132.1M21.0%
MARCUS DALY MEMORIAL HOSPITALMT25$107.6M-1.3%
LOGAN HEALTH WHITEFISHMT25$101.8M13.8%
SIDNEY HEALTH CENTERMT25$95.2M-6.3%
NORTHERN MONTANA HOSPITALMT49$93.3M-4.7%
COMMUNITY HOSPITAL OF ANACONDAMT25$89.0M1.3%
LIVINGSTON HEALTHCAREMT25$72.6M-7.1%
HOLY ROSARY HEALTHCAREMT25$67.3M1.3%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $534K (749bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$150K+210bp18mo
Denial Rate Reduction12.0%6.5%$145K+204bp12mo
Cost to Collect4.5%2.5%$142K+200bp12mo
A/R Days Reduction5200.0%3800.0%$87K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+13bp6mo

5. EBITDA Bridge

Net Collection Rate
$150K
Denial Rate Reduction
$145K
Cost to Collect
$142K
A/R Days Reduction
$87K
Clean Claim Rate
$10K
Total EBITDA Uplift$534K
Current EBITDA$-471K
+ RCM Uplift+$534K
Pro Forma EBITDA$63K
Current Margin-6.6%
Pro Forma Margin0.9%
WC Released (1x)$273K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-725K$2.2M0.00x-100.0%
Base (11x exit)10.0x11.0x$-725K$2.2M0.00x-100.0%
Bull Case9.0x11.0x$-652K$3.7M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-652K$3.9M0.00x-100.0%
Bear Case11.0x10.0x$-797K$-203K0.00x-100.0%
Bear (11x exit)11.0x11.0x$-797K$-482K0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 57.0% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 48 hospitals with 12-50 beds
  • Same-state prioritization (n=49)
  • Comp margins: P25=-20.8% / P50=-9.3% / P75=-1.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.